Principal Investigator
Overview
Start/End Dates
Locations
UBC Hospital
Name/Title
Laura Harvey, Research Coordinator
Phone
Email Address
Purpose of Study
Primary Objective:
- To evaluate long-term safety of alemtuzumab.
Secondary Objectives:
- To evaluate long term efficacy of alemtuzumab. To evaluate the safety profile of patients who received other Disease Modifying Treatment's (DMT) following alemtuzumab treatment.
- To evaluate patient-reported Quality of Life (QoL) outcomes and health resource utilization of patients who received alemtuzumab.
- To evaluate as needed re-treatment with alemtuzumab and other DMTs.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.
Start/End Dates
Locations
UBC Hospital
Name/Title
Laura Harvey, Research Coordinator
Phone
Email Address
Purpose of Study
Primary Objective:
- To evaluate long-term safety of alemtuzumab.
Secondary Objectives:
- To evaluate long term efficacy of alemtuzumab. To evaluate the safety profile of patients who received other Disease Modifying Treatment's (DMT) following alemtuzumab treatment.
- To evaluate patient-reported Quality of Life (QoL) outcomes and health resource utilization of patients who received alemtuzumab.
- To evaluate as needed re-treatment with alemtuzumab and other DMTs.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.
